EGF and cancer: Considering the presence of ULD of growth factors in MIM-4 formulation, hr-EGF (27 CH) and hr-TGF-β (27 CH) (see Table 1), and, as the rationale of this specific CH is the intention to disrupt EGF- and TGF-β-related-pathways in CRC cells, we wanted to avoid any exogenous supply of growth factors to the cancer cells, which are normally provided by fetal bovine serum (FBS).